Van Leeuwen & Company LLC Sells 13,791 Shares of Johnson & Johnson (NYSE:JNJ)

Van Leeuwen & Company LLC cut its position in Johnson & Johnson (NYSE:JNJGet Rating) by 52.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,294 shares of the company’s stock after selling 13,791 shares during the quarter. Van Leeuwen & Company LLC’s holdings in Johnson & Johnson were worth $2,103,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Steward Financial Group LLC bought a new position in shares of Johnson & Johnson during the fourth quarter worth about $34,000. Jackson Wealth Management LLC increased its holdings in Johnson & Johnson by 1.7% in the third quarter. Jackson Wealth Management LLC now owns 16,959 shares of the company’s stock worth $40,000 after purchasing an additional 277 shares in the last quarter. Iron Horse Wealth Management LLC increased its holdings in Johnson & Johnson by 29.9% in the fourth quarter. Iron Horse Wealth Management LLC now owns 265 shares of the company’s stock worth $45,000 after purchasing an additional 61 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. increased its holdings in Johnson & Johnson by 290.7% in the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 293 shares of the company’s stock worth $47,000 after purchasing an additional 218 shares in the last quarter. Finally, Bell Investment Advisors Inc bought a new stake in Johnson & Johnson in the third quarter worth approximately $76,000. Hedge funds and other institutional investors own 68.78% of the company’s stock.

In related news, insider William Hait sold 29,699 shares of the business’s stock in a transaction dated Thursday, April 21st. The stock was sold at an average price of $183.58, for a total transaction of $5,452,142.42. Following the completion of the transaction, the insider now directly owns 80,236 shares in the company, valued at $14,729,724.88. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, VP Thibaut Mongon sold 23,681 shares of the company’s stock in a transaction dated Thursday, March 17th. The stock was sold at an average price of $176.25, for a total value of $4,173,776.25. The disclosure for this sale can be found here. Insiders own 0.35% of the company’s stock.

Shares of NYSE:JNJ traded up $1.05 during mid-day trading on Friday, hitting $180.51. 285,280 shares of the company traded hands, compared to its average volume of 7,863,764. The stock has a market cap of $474.99 billion, a P/E ratio of 24.19, a P/E/G ratio of 2.87 and a beta of 0.66. The company has a current ratio of 1.39, a quick ratio of 1.14 and a debt-to-equity ratio of 0.39. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69. The stock has a 50-day moving average price of $178.96 and a two-hundred day moving average price of $171.30.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its earnings results on Tuesday, April 19th. The company reported $2.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.60 by $0.07. The company had revenue of $23.43 billion for the quarter, compared to analysts’ expectations of $23.62 billion. Johnson & Johnson had a return on equity of 36.59% and a net margin of 20.90%. Johnson & Johnson’s quarterly revenue was up 5.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.59 earnings per share. As a group, analysts expect that Johnson & Johnson will post 10.2 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 7th. Shareholders of record on Tuesday, May 24th will be paid a $1.13 dividend. The ex-dividend date is Monday, May 23rd. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.06. This represents a $4.52 annualized dividend and a dividend yield of 2.50%. Johnson & Johnson’s payout ratio is presently 60.92%.

A number of brokerages have weighed in on JNJ. The Goldman Sachs Group lifted their target price on Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a report on Tuesday, April 12th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, May 17th. Sanford C. Bernstein cut Johnson & Johnson from an “outperform” rating to a “market perform” rating and raised their price objective for the company from $180.00 to $183.00 in a research note on Wednesday, March 16th. Citigroup reduced their price objective on Johnson & Johnson from $210.00 to $205.00 in a research note on Tuesday, May 17th. Finally, Raymond James raised their price objective on Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a research note on Wednesday, April 20th. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson has an average rating of “Buy” and an average price target of $187.86.

Johnson & Johnson Profile (Get Rating)

Johnson & Johnson researches and develops, manufactures, and sells various products in the healthcare field worldwide. It operates in three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.